Gene Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene Symbol ATR
Synonyms FCTCS | FRP1 | MEC1 | SCKL | SCKL1
Gene Description ATR, ATR serine/threonine kinase, is involved in regulation of the DNA damage response and mediation of cell-cycle checkpoints (PMID: 25512053). Loss of function ATR mutations have been identified in melanoma (PMID: 28273450), and inhibition of Atr selectively sensitizes cancerous cells to radiation and chemotherapy (PMID: 23583268, PMID: 31836456, PMID: 29054375).
NCBI Gene ID Chromosome Map Location Canonical Transcript Gene Role
545 3 3q23 NM_001184 Tumor suppressor (PMID: 30606230)

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ATR over exp chronic lymphocytic leukemia predicted - sensitive Ceralasertib Preclinical Actionable In a preclinical study, chronic lymphocytic leukemia cells expressing ATR were sensitive to AZD6738 (Cancer Res October 1, 2014 74; 5485). detail...
ATR inact mut prostate cancer sensitive Enzalutamide + Talazoparib FDA approved Actionable In a Phase III trial (TALAPRO-2) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median radiographic progression-free survival compared to enzalutamide plus placebo (27.9 vs 16.4 mo, HR 0.46, p=0.0003) in patients with metastatic castration-resistant prostate cancer harboring deficient homologous recombination repair genes including ATR, with an HR of 0.66 (p=0.12) in patients with non-BRCA mutations treated with Talzenna (talazoparib) (PMID: 37285865; NCT03395197). detail... 37285865
ATR inact mut prostate cancer sensitive Enzalutamide + Talazoparib Guideline Actionable Talzenna (talazoparib) plus Xtandi (enzalutamide) is included in guidelines as systemic therapy for patients with metastatic castration-resistant prostate cancer harboring a pathogenic germline or somatic ATR mutation who have not been treated in the setting of castration-resistant prostate cancer (NCCN.org). detail...
ATR positive breast cancer predicted - sensitive VE-821 Preclinical - Cell culture Actionable In a preclinical study, human breast cancer cell lines demonstrated sensitivity to VE-821 in culture, resulting in decreased cell survival (PMID: 25468710). 25468710
ATR positive lung cancer sensitive Berzosertib + Cisplatin Preclinical - Pdx & cell culture Actionable In a preclinical study, Berzosertib (VX-970) sensitized patient-derived lung cancer cells to Platinol (cisplatin) in culture and in patient-derived xenograft (PDX) models (PMID: 25010037). 25010037
ATM del ATR dec exp Advanced Solid Tumor decreased response PJ34 Preclinical - Cell culture Actionable In a preclinical study, ATM-null transformed cells with decreased Atr expression demonstrated decreased sensitivity to PJ34 in culture (PMID: 21840268). 21840268